Insight
Neoadjuvant durvalumab improves survival in early TNBC independent of pathological complete response
apollohospitals.com

Neoadjuvant durvalumab improves survival in early TNBC independent of pathological complete response

Akhil Santhosh, Medical Oncologist at Dr BR Ambedkar Institute Rotary Cancer Hospital, shared a post on X:

“Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response.

  • Small randomised phase 2 trial
  • Used durva only in neoadjuvant phase with nab pacli and dose dense EC

Authors: S. Loibl, A. Schneeweiss, J. Huober, M. Braun, J. Rey, J.-U. Blohmer, J. Furlanetto, D.-M. Zahm, C. Hanusch, J. Thomalla, C. Jackisch, P. Staib, T. Link, K. Rhiem, C. Solbach, P.A. Fasching, V. Nekljudova, C. Denkert, M. Untch.

Neoadjuvant durvalumab improves survival in early TNBC independent of pathological complete response

Neoadjuvant durvalumab improves survival in early TNBC independent of pathological complete response

  • One seperate window cohort where single dose of durva given 2 weeks prior
  • Primary endpoint point was PCR, study was heavily powered for the same, which was not met(insignificant increase)
  • Improved Disease-Free Survival, DDFS and Overall Survival, but all are exploratory analyses with no relevant meaning
  • Improvement in path Cr irrespective of PDL1 expression, Residual Stromal TILS prognostic for improved IDFS .”
A. Schneeweiss Akhil Santhosh Breast Cancer C. Denkert C. Hanusch C. Jackisch C. Solbach cancer D.-M. Zahm DDFS Disease-Free Survival (DFS) Durva IDFS J. Furlanetto J. Huober J. Rey J. Thomalla J.-U. Blohmer K. Rhiem M. Braun M. Untch OncoDaily Oncology Overall survival (OS) P. Staib P.A. Fasching pCR PDL1 expression S. Loibl T. Link TILs V. Nekljudova